Shares of Eli Lilly and Company (NYSE:LLY - Get Free Report) were up 4% during trading on Thursday . The stock traded as high as $1,149.10 and last traded at $1,126.6560. Approximately 4,585,704 shares changed hands during trading, an increase of 44% from the average daily volume of 3,194,030 shares. The stock had previously closed at $1,082.92.
Key Headlines Impacting Eli Lilly and Company
Here are the key news stories impacting Eli Lilly and Company this week:
- Positive Sentiment: CVS Caremark is restoring coverage for Zepbound and adding Lilly’s new obesity pill Foundayo to standard drug plans, meaning all three major PBMs now cover Lilly’s full obesity portfolio. Reuters article
- Positive Sentiment: Lilly said the expanded PBM coverage could make its obesity medicines accessible to millions more patients and support lower out-of-pocket costs, which is a positive for demand and market share. PR Newswire article
- Positive Sentiment: The company also unveiled strong late-stage data for Foundayo and retatrutide ahead of the ADA conference, reinforcing confidence in Lilly’s obesity and diabetes pipeline. PR Newswire article
- Positive Sentiment: Several analysts reiterated bullish views, with some raising price targets and calling Lilly a strong long-term growth story, which can add to investor optimism. InsiderMonkey article
Wall Street Analyst Weigh In
Several analysts recently commented on LLY shares. Guggenheim reissued a "buy" rating and set a $1,183.00 target price on shares of Eli Lilly and Company in a research note on Tuesday, May 5th. CICC Research increased their target price on shares of Eli Lilly and Company from $1,060.00 to $1,107.00 and gave the company a "neutral" rating in a research note on Wednesday, February 11th. Royal Bank Of Canada reissued an "outperform" rating on shares of Eli Lilly and Company in a research note on Thursday, May 21st. Bank of America increased their target price on shares of Eli Lilly and Company from $1,133.00 to $1,251.00 and gave the company a "buy" rating in a research note on Tuesday. Finally, Truist Financial reissued a "buy" rating on shares of Eli Lilly and Company in a research note on Monday, February 23rd. Two research analysts have rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average price target of $1,227.00.
View Our Latest Stock Analysis on LLY
Eli Lilly and Company Trading Up 4.0%
The company has a current ratio of 1.50, a quick ratio of 1.10 and a debt-to-equity ratio of 1.26. The firm has a market cap of $1.06 trillion, a PE ratio of 40.02, a P/E/G ratio of 1.16 and a beta of 0.48. The company's 50-day moving average is $948.23 and its 200 day moving average is $1,007.67.
Eli Lilly and Company (NYSE:LLY - Get Free Report) last issued its quarterly earnings results on Thursday, April 30th. The company reported $8.55 EPS for the quarter, beating the consensus estimate of $6.97 by $1.58. The business had revenue of $19.80 billion during the quarter, compared to the consensus estimate of $17.82 billion. Eli Lilly and Company had a net margin of 34.98% and a return on equity of 105.77%. The firm's quarterly revenue was up 55.5% on a year-over-year basis. During the same quarter in the prior year, the firm earned $3.34 EPS. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. As a group, sell-side analysts predict that Eli Lilly and Company will post 35.82 EPS for the current year.
Eli Lilly and Company Dividend Announcement
The company also recently declared a quarterly dividend, which will be paid on Wednesday, June 10th. Investors of record on Friday, May 15th will be given a $1.73 dividend. This represents a $6.92 annualized dividend and a dividend yield of 0.6%. The ex-dividend date is Friday, May 15th. Eli Lilly and Company's dividend payout ratio is 24.58%.
Institutional Investors Weigh In On Eli Lilly and Company
Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Cozad Asset Management Inc. lifted its position in Eli Lilly and Company by 2.1% in the 1st quarter. Cozad Asset Management Inc. now owns 22,031 shares of the company's stock worth $20,263,000 after buying an additional 452 shares in the last quarter. Allen Capital Group LLC lifted its position in Eli Lilly and Company by 0.8% in the 1st quarter. Allen Capital Group LLC now owns 1,918 shares of the company's stock worth $1,764,000 after buying an additional 16 shares in the last quarter. Security Financial Services INC. lifted its position in Eli Lilly and Company by 2.0% in the 1st quarter. Security Financial Services INC. now owns 1,281 shares of the company's stock worth $1,178,000 after buying an additional 25 shares in the last quarter. Axiom Investment Management LLC purchased a new stake in Eli Lilly and Company in the 1st quarter worth approximately $1,297,000. Finally, Summitry LLC lifted its position in Eli Lilly and Company by 76.0% in the 1st quarter. Summitry LLC now owns 1,477 shares of the company's stock worth $1,358,000 after buying an additional 638 shares in the last quarter. Hedge funds and other institutional investors own 82.53% of the company's stock.
About Eli Lilly and Company
(
Get Free Report)
Eli Lilly and Company NYSE: LLY is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Eli Lilly and Company, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Eli Lilly and Company wasn't on the list.
While Eli Lilly and Company currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
